Certified Software Solutions Quality Forum October, 2003 Vol.1 No. 7

Validation Planning Using Safety Risk Management

By: Curtis M. Egan and Dan P. Olivier

This paper will address the topic of validation planning based on information gathered from safety risk management. Safety risk management is becoming increasingly recognized as an important method to support definition of the essential requirements for validation processes and medical device products.

This paper will also highlight and identify where risk management can be applied and suggest approaches to optimize the validation process by using a risk management process. The techniques discussed in this paper are based on industry standard processes and definitions that have been tailored based on our experience with use of these methods for hundreds of processes supporting dozens of pharmaceutical products and medical devices.



Approach

Use of risk management techniques to support regulatory compliance decisions has been endorsed by the FDA as shown in the new approach for the Pharmaceutical CGMP, Guidance for Part 11 Scope and Application, and the Quality Systems Inspection Technique (QSIT) audit methodology. This paper will discuss a generalized approach to support each of these areas based on a risk management strategy as derived from ISO 14971, Application of risk management to medical devices, and the Good Automated Manufacturing Processes (GAMP) Guide for Validation of Automated Systems. This paper will demonstrate how information from risk management can be used logically to plan validation tasks.

Certified Software Solutions Quality Forum October, 2003 Certified Software Solutions Vol.1 No. 7

How can Risk Assessments Streamline my Validation Planning?

Risk based methods not only help minimize compliance risk but also provide an excellent tool for achieving business benefits. Use of risk based methods forces a detailed focus on the most critical elements of the process or product and therefore a less detailed focus on other less important functions. This focus has allowed many pharmaceutical companies to reduce the level of validation detail for minor functions while remaining confident that all regulatory and quality/safety related requirements has been thoroughly addressed.

Use of a risk management process can provide significant business and regulatory compliance benefits. Table 1 lists different applications where a safety risk management process can be applied to streamline validation activities and provide increased confidence in product design and manufacturing. It can be seen from this list that the application of risk-based models not only has a very wide scope, but also is heavily endorsed and encouraged by the FDA as well as in regulatory references such as GAMP.

| | Application | How Used | Reference |
|----|-----------------------------|---------------------------------|------------------------------|
| 1. | Determines the level of | Define documentation based | Reviewer Guidance for |
| | documentation detail | on the level of concern or | Computer Controlled |
| | required for FDA | safety risk to a patient | Medical Devices ⁶ |
| | submissions | | |
| 2. | Determine reportable events | Formal process for evaluation | Compliance with the |
| | for Adverse Events Reports | of events to determine if they | Adverse Event |
| | | meet the adverse event criteria | Reporting regulation 21 |
| | | | CFR Part 314.80 ⁷ |
| 3. | Determine reportable events | Defines criteria for evaluating | Compliance with the |
| | for Medical Device Reports | potential for recurrence of an | Medical Device |
| | | event that could contribute to | Reporting regulation, 21 |
| | | serious injury or death | CFR Part 803 ⁸ |
| 4. | Determine Part 11 | Defines the scope of | Final Guidance for 21 |
| | applicability and | validation and compliance | CFR Part 11 Scope and |
| | requirements | requirements | Application ² |

C55 Quality Forum

| | Application | How Used | Reference |
|-----|-------------------------------|---------------------------------|-----------------------------------|
| 5. | Determine what | Defines critical control points | Hazard Analysis of |
| | manufacturing processes | to select systems and | Critical Control Points, |
| | and parameters require | parameters for validation | FDA training program ⁹ |
| | validation | | |
| 6. | Determine priority for | Defines criteria for | GAMP Guide for |
| | fixing product/process | prioritizing which outstanding | validation of Automated |
| | defects | defects must be corrected | Systems, GAMP 4 ⁵ |
| 7. | Focus audits on critical | Defines most important | FDA's Quality System |
| | systems | subsystems to be audited to | Inspection Technique |
| | | reduce audit scope | (QSIT) ³ |
| 8. | Determine level of detail for | Defines functions that should | GAMP Guide for |
| | functional requirements and | be supported by more detailed | validation of Automated |
| | design | definition and test activities | Systems, GAMP 4 ⁵ |
| 9. | Determine requirements for | Defines criteria for which | GAMP Guide for |
| | supplier audits | suppliers should be audited | validation of Automated |
| | | | Systems, GAMP 4 ⁵ |
| 10. | Determine regulatory | Use of a risk based orientation | FDA's Pharmaceutical |
| | requirements for public | for the development of new | CGMPs for the 21 st |
| | health protection | Pharmaceutical CGMPs | Century: A Risk-Based |
| | | | Approach ¹ |

Table 1 Safety Risk Analysis Methods

A risk assessment can also be used to identify the level of validation required based on established requirements and safety risks. This requires the validation team to consider and identify safety considerations prior to creating validation protocols. Identification of the following elements will help streamline validation tasks:

- Identification of hardware components where failures can lead to an unsafe product.
- Identification of processing algorithms that are safety related (i.e.).
- Identifications of sensors, alarms, and interlocks where



Certified Software Solutions, Inc.



failure could result in the inability to detect or prevent a bad product or operator injury.

- Identification of operator input data or command sequences that can lead to an out of specification product.
- Identification of "critical control points" that capture out of range conditions that could lead to a safety related failure.

How do I Implement Risk Management Based Validation?



The standard flow of safety risk analysis is Risk Analysis, Risk Evaluation, Risk Control and Change Control (as discussed in Quality Forum #6, December 2002, Safety Risk Management, by Chad Osborne and Dan Olivier. www.certifiedsofteware.com/qualityforum /qualityforum.htm). Risk Management can identify failure conditions, and fail safe responses. This can directly influence testing strategy, protocols and activities. This mode can also assist in the definition of specific data to be entered during testing and the expected results for each entry, as well as in the identification of normal, boundary and out of range conditions that need to be verified and validated. It also gives focus to parameters that have safety consequences. and defines acceptance criteria identified in the risk identification process.

The risk control phase includes the definition of the safety requirements and requires verification that the controls are effective in achieving the target level of safety. This means that the defined safety requirements must be verified and/or validated in accordance with established procedures. Based on the results of the verification/validation phases, it may be appropriate to reassess the estimated risk and confirm the accuracy of the estimated probabilities of occurrence and detectability of fault conditions.

It should be noted however that the "intended use" of the product must be defined before any risk analysis can be conducted. The definition of the intended use is necessary to define the product labeling to specify performance limits. Adequacy and completeness of the customer labeling in terms of Cautions and Warnings is essential to provide for customer protection, to satisfy regulatory requirements, and to reduce civil liability. Again the intended use correlates directly to the validation process. The intended use will give further focus to validation efforts reducing the number of unnecessary test cases.



Summary

The benefits obtained from the use of risk management methods are becoming increasingly acknowledged by medical and pharmaceutical manufacturers as well as by regulatory bodies such as the FDA. Optimal use of these methods will provided an excellent strategy to streamline validation activities for products as well as processes and also offers a technique that can instill increased confidence in the safety of established products and processes. Familiarity and competence in the conduct of risk management techniques is increasingly becoming a critical skill for quality and regulatory professionals.

References:

- 1. <u>Pharmaceutical CGMPs for the 21st Century: A Risk-Based Approach; A Science and Risk-Based Approach to Product Quality Regulation Incorporating an Integrated Quality Systems Approach, (FDA 2002). (CGMPs)</u>
- 2. <u>Guidance for Industry: Part 11, Electronic Records; Electronic Signatures Scope and Application</u>, Division of Drug Information, HFD-240, Center for Drug Evaluation and Research (CDER), August 2003. (Part 11)
- 3. <u>Quality System Inspection Technique Handbook</u>, Food and Drug Administration, Center for Devices and Radiological Health, August 1999. (QSIT)
- 4. <u>Medical device Application of safety risk management to medical devices</u>, ANSI/AAMI/ISO 14971:2000.
- 5. <u>The Good Automated Manufacturing Practice (GAMP) Guide for Validation of Automated Systems</u>, GAMP 4 (ISPE/GAMP Forum, 2001)
- 6. Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, FDA, Office of Device Evaluation, May 29, 1998.
- 7. 21 CFR Part 314.80 <u>Postmarketing reporting of adverse drug experience</u>, Federal Register.
- 8. 21 CFR Part 803, Medical device reporting, Federal Register.
- 9. <u>HACCP (Hazard Analysis and Critical Control Points) for Medical Devices</u>, FDA CDRH, October 17, 1997.

Dan Olivier is president of Certified Software Solutions, Inc., and is a recognized industry expert in safety risk management and verification and validation of manufacturing processes. Dan has authored numerous articles on engineering activities and is a frequent speaker at industry conferences.

Curtis Egan is a Software Quality Engineer with Certified Software Solutions, Inc., and a validation expert. He has been with the company for three years.



Spotlight on Products: Executive Vision NCMR

Give us a call at (858) 675-8200 or visit our web site at www.certifiedsoftware.com for more information. Let us know how we can help you.